Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle.
Department of Health Services, School of Public Health, University of Washington, Seattle.
JAMA. 2014 Aug 6;312(5):492-501. doi: 10.1001/jama.2014.7860.
Although brief intervention is effective for reducing problem alcohol use, few data exist on its effectiveness for reducing problem drug use, a common issue in disadvantaged populations seeking care in safety-net medical settings (hospitals and community health clinics serving low-income patients with limited or no insurance).
To determine whether brief intervention improves drug use outcomes compared with enhanced care as usual.
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial with blinded assessments at baseline and at 3, 6, 9, and 12 months conducted in 7 safety-net primary care clinics in Washington State. Of 1621 eligible patients reporting any problem drug use in the past 90 days, 868 consented and were randomized between April 2009 and September 2012. Follow-up participation was more than 87% at all points.
Participants received a single brief intervention using motivational interviewing, a handout and list of substance abuse resources, and an attempted 10-minute telephone booster within 2 weeks (n = 435) or enhanced care as usual, which included a handout and list of substance abuse resources (n = 433).
The primary outcomes were self-reported days of problem drug use in the past 30 days and Addiction Severity Index-Lite (ASI) Drug Use composite score. Secondary outcomes were admission to substance abuse treatment; ASI composite scores for medical, psychiatric, social, and legal domains; emergency department and inpatient hospital admissions, arrests, mortality, and human immunodeficiency virus risk behavior.
Mean days used of the most common problem drug at baseline were 14.40 (SD, 11.29) (brief intervention) and 13.25 (SD, 10.69) (enhanced care as usual); at 3 months postintervention, means were 11.87 (SD, 12.13) (brief intervention) and 9.84 (SD, 10.64) (enhanced care as usual) and not significantly different (difference in differences, β = 0.89 [95% CI, -0.49 to 2.26]). Mean ASI Drug Use composite score at baseline was 0.11 (SD, 0.10) (brief intervention) and 0.11 (SD, 0.10) (enhanced care as usual) and at 3 months was 0.10 (SD, 0.09) (brief intervention) and 0.09 (SD, 0.09) (enhanced care as usual) and not significantly different (difference in differences, β = 0.008 [95% CI, -0.006 to 0.021]). During the 12 months following intervention, no significant treatment differences were found for either variable. No significant differences were found for secondary outcomes.
A one-time brief intervention with attempted telephone booster had no effect on drug use in patients seen in safety-net primary care settings. This finding suggests a need for caution in promoting widespread adoption of this intervention for drug use in primary care.
clinicaltrials.gov Identifier: NCT00877331.
尽管简短干预对减少问题性饮酒有效,但关于其对减少弱势人群中常见的问题性药物使用的有效性的数据很少,这些人群在寻求医疗服务时处于不利地位,通常在安全网医疗环境(为低收入患者提供服务的医院和社区卫生诊所,这些患者没有或只有有限的保险)中。
确定简短干预是否比增强的常规护理更能改善药物使用结果。
设计、地点和参与者:这是一项随机临床试验,在华盛顿州的 7 家安全网初级保健诊所进行,在基线和 3、6、9 和 12 个月时进行了盲法评估。在过去 90 天内报告有任何问题性药物使用的 1621 名合格患者中,有 868 名同意并在 2009 年 4 月至 2012 年 9 月期间随机分为两组:接受单次简短干预的患者使用动机性访谈、一份药物滥用资源清单和一份在 2 周内(n = 435)进行的 10 分钟电话增强剂,或接受增强的常规护理,包括一份药物滥用资源清单(n = 433)。
参与者接受了单次简短干预,包括使用动机性访谈、一份药物滥用资源清单和一份在 2 周内(n = 435)进行的 10 分钟电话增强剂,或接受增强的常规护理,包括一份药物滥用资源清单(n = 433)。
主要结果是过去 30 天内自我报告的问题性药物使用天数和成瘾严重程度指数-简化版(ASI)药物使用综合评分。次要结果是接受药物滥用治疗的情况;ASI 综合评分在医疗、精神科、社会和法律领域;急诊室和住院医院入院、逮捕、死亡率和人类免疫缺陷病毒风险行为。
基线时最常见问题性药物的平均使用天数为 14.40(SD,11.29)(简短干预)和 13.25(SD,10.69)(增强常规护理);干预后 3 个月时,平均值分别为 11.87(SD,12.13)(简短干预)和 9.84(SD,10.64)(增强常规护理),无显著差异(差异,β=0.89 [95%CI,-0.49 至 2.26])。基线时 ASI 药物使用综合评分分别为 0.11(SD,0.10)(简短干预)和 0.11(SD,0.10)(增强常规护理),3 个月时分别为 0.10(SD,0.09)(简短干预)和 0.09(SD,0.09)(增强常规护理),无显著差异(差异,β=0.008 [95%CI,-0.006 至 0.021])。在干预后的 12 个月内,两种变量均未发现治疗差异显著。次要结果无显著差异。
在安全网初级保健环境中就诊的患者中,单次简短干预加电话增强剂干预对药物使用没有影响。这一发现表明,在促进将这种干预广泛应用于初级保健中的药物使用时需要谨慎。
clinicaltrials.gov 标识符:NCT00877331。